US 12,274,809 B2
Biomimetic nano-composite scaffold for enhanced bone healing and fracture repair
Atharva Abhay Poundarik, Troy, NY (US); Marta Monteiro Silva Carvalho, Lisbon (PT); and Deepak Vashishth, Glenmont, NY (US)
Assigned to RENSSELAER POLYTECHNIC INSTITUTE, Troy, NY (US)
Appl. No. 15/570,942
Filed by RENSSELAER POLYTECHNIC INSTITUTE, Troy, NY (US)
PCT Filed May 2, 2016, PCT No. PCT/US2016/030410
§ 371(c)(1), (2) Date Oct. 31, 2017,
PCT Pub. No. WO2016/179089, PCT Pub. Date Nov. 10, 2016.
Claims priority of provisional application 62/290,628, filed on Feb. 3, 2016.
Claims priority of provisional application 62/155,684, filed on May 1, 2015.
Prior Publication US 2018/0280570 A1, Oct. 4, 2018
Int. Cl. A61L 27/26 (2006.01); A61F 13/00 (2006.01); A61L 27/12 (2006.01); A61L 27/46 (2006.01); A61L 27/54 (2006.01)
CPC A61L 27/26 (2013.01) [A61F 13/00 (2013.01); A61F 13/00063 (2013.01); A61L 27/12 (2013.01); A61L 27/46 (2013.01); A61L 27/54 (2013.01); A61L 2300/414 (2013.01); A61L 2300/64 (2013.01); A61L 2430/02 (2013.01)] 8 Claims
OG exemplary drawing
 
1. An article comprising:
an orthopedic implant including a surface; and
a coating disposed on the surface, the coating including a tissue mineralization-promoting sub stance,
wherein the substance includes type I collagen, calcium phosphate, osteopontin, osteocalcin, and a compound that removes advanced glycation endproducts (AGEs),
wherein the concentration of osteopontin in the substance is about 0.06 μg and the concentration of osteocalcin in the substance is about 0.3 μg,
wherein at least one of a plurality of osteopontin molecules are enzymatically cross-linked to type-I collagen.